Compare · AKLI vs RMD
AKLI vs RMD
Side-by-side comparison of Akili Inc. (AKLI) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AKLI and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD carries a market cap of $33.32B.
- RMD has hit the wire 14 times in the past 4 weeks while AKLI has been quiet.
- RMD has more recent analyst coverage (25 ratings vs 0 for AKLI).
- Company
- Akili Inc.
- ResMed Inc.
- Price
- -
- -
- Market cap
- -
- $33.32B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 14
- Recent ratings
- 0
- 25
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest AKLI
- PureTech Health plc – Half-Year Report
- SEC Form 15-12G filed by Akili Inc.
- SEC Form EFFECT filed by Akili Inc.
- Amendment: SEC Form SC 13D/A filed by Akili Inc.
- SEC Form 4 filed by Large owner Puretech Health Plc
- SEC Form 4 filed by Large owner Palihapitiya Chamath
- Amendment: SEC Form SC 13D/A filed by Akili Inc.
- Amendment: SEC Form SC 13G/A filed by Akili Inc.
- SEC Form 4 filed by Large owner Temasek Holdings (Private) Ltd
- President & CEO Franklin Matthew returned 33,000 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest RMD
- ResMed Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Jan De Witte sold $101,673 worth of ResMed Common Stock (429 units at $237.00) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 3,772 units (SEC Form 4)
- Chairman and CEO Farrell Michael J. covered exercise/tax liability with 8,111 units of ResMed Common Stock, decreasing direct ownership by 2% to 471,774 units (SEC Form 4) (tax withholding)
- Chief Financial Officer Bloomer Aaron covered exercise/tax liability with 1,095 units of ResMed Common Stock, decreasing direct ownership by 12% to 7,977 units (SEC Form 4) to satisfy withholding tax
- Director Farrell Peter C covered exercise/tax liability with 169 units of ResMed Common Stock, decreasing direct ownership by 0.33% to 51,634 units (SEC Form 4) (withholding obligation)
- Director De Witte Jan covered exercise/tax liability with 60 units of ResMed Common Stock, decreasing direct ownership by 1% to 4,201 units (SEC Form 4) (for tax liability)
- Director Gill Harjit covered exercise/tax liability with 36 units of ResMed Common Stock, decreasing direct ownership by 0.33% to 10,904 units (SEC Form 4) (withholding tax)
- Global General Counsel Rider Michael J covered exercise/tax liability with 1,944 units of ResMed Common Stock, decreasing direct ownership by 16% to 10,417 units (SEC Form 4) (withholding obligation)
- Chairman and CEO Farrell Michael J. exercised 4,993 units of ResMed Common Stock at a strike of $146.34 and sold $1,175,089 worth of ResMed Common Stock (4,993 units at $235.35) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed downgraded by Canaccord Genuity